Akebia Therapeutics (AKBA)

Apr 3, 2025, 8:00 AM EDT - 22 days ago

Akebia Therapeutics Announces Positive Opinion of European Medicines Agency for XOANACYL®, an Oral Therapy for Chronic Kidney Disease Licensed to Averoa

Apr 2, 2025, 4:05 PM EDT - 23 days ago

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 25, 2025, 8:00 AM EDT - 4 weeks ago

Akebia Therapeutics Announces Poster Presentations at NKF Spring Clinical Meetings 2025

Mar 20, 2025, 8:18 AM EDT - 5 weeks ago

JOYY, Akebia Therapeutics, Microchip Technology And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

MCHP

Mar 19, 2025, 10:17 PM EDT - 5 weeks ago

Akebia Therapeutics Announces Pricing of Public Offering of Common Stock

Mar 19, 2025, 4:01 PM EDT - 5 weeks ago

Akebia Therapeutics Announces Proposed Public Offering of Common Stock

Mar 13, 2025, 10:21 AM EDT - 6 weeks ago

Akebia Therapeutics, Inc. (AKBA) Q4 2024 Earnings Call Transcript

Mar 13, 2025, 7:00 AM EDT - 6 weeks ago

Akebia Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Vafseo® (vadadustat) Commercial Launch Progress Update

Mar 6, 2025, 8:00 AM EST - 7 weeks ago

Akebia Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Discuss Recent Business Highlights

Feb 10, 2025, 5:43 AM EST - 2 months ago

Akebia Therapeutics: Still Bullish On Vafseo As Auryxia's Revenues Decline

Feb 4, 2025, 4:05 PM EST - 2 months ago

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 13, 2025, 8:00 AM EST - 3 months ago

Akebia Therapeutics Announces Multiple Positive Business Updates

Dec 18, 2024, 8:00 AM EST - 4 months ago

Akebia Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 3, 2024, 7:00 AM EST - 5 months ago

U.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo® (vadadustat) for CKD Patients on Dialysis

Nov 25, 2024, 8:00 AM EST - 5 months ago

Akebia Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference

Nov 20, 2024, 3:31 PM EST - 5 months ago

Q3 2024 Earnings: Hold Akebia Therapeutics

Nov 14, 2024, 8:00 AM EST - 5 months ago

Vadadustat Alternative Dosing Study Results Published in the American Journal of Kidney Disease

Nov 12, 2024, 8:00 AM EST - 5 months ago

Akebia Therapeutics to Present at the Jefferies London Healthcare Conference

Nov 7, 2024, 1:59 PM EST - 6 months ago

Akebia Therapeutics, Inc. (AKBA) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 7:00 AM EST - 6 months ago

Akebia Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Nov 1, 2024, 8:00 AM EDT - 6 months ago

Akebia Therapeutics to Report Third Quarter 2024 Financial Results and Discuss Recent Business Highlights

Oct 22, 2024, 8:00 AM EDT - 6 months ago

Akebia Therapeutics Signs Commercial Supply Contract with Leading Dialysis Organization to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis

Oct 15, 2024, 8:00 AM EDT - 6 months ago

Akebia Therapeutics Announces Seven Poster Presentations at ASN Kidney Week 2024

Oct 10, 2024, 8:00 AM EDT - 7 months ago

CMS Grants TDAPA Reimbursement for Vafseo® (vadadustat) beginning January 1, 2025

Oct 7, 2024, 8:00 AM EDT - 7 months ago

Akebia Therapeutics and U.S. Renal Care Sign Commercial Supply Contract to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis

Sep 5, 2024, 8:00 AM EDT - 8 months ago

Akebia Therapeutics and U.S. Renal Care Initiate the VOICE Trial of Vafseo® (vadadustat) for Patients on Dialysis

Aug 26, 2024, 8:00 AM EDT - 8 months ago

Akebia Therapeutics to Present at Upcoming Investor Conferences

Aug 10, 2024, 1:00 AM EDT - 9 months ago

Akebia Therapeutics, Inc. (AKBA) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 7:00 AM EDT - 9 months ago

Akebia Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Aug 2, 2024, 8:00 AM EDT - 9 months ago

Akebia Therapeutics to Report Second Quarter 2024 Financial Results and Discuss Recent Business Highlights

Jul 11, 2024, 6:00 AM EDT - 10 months ago

Akebia Therapeutics Provides Update on Continued Momentum of Commercial Launch of Vafseo® (vadadustat) Tablets

Jun 27, 2024, 8:18 AM EDT - 10 months ago

Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference

Jun 24, 2024, 8:58 AM EDT - 10 months ago

Akebia Therapeutics Appoints Erik Ostrowski as Chief Financial Officer and Chief Business Officer

May 23, 2024, 8:00 AM EDT - 1 year ago

Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference

May 14, 2024, 8:00 AM EDT - 1 year ago

Akebia Therapeutics to Present at the 2nd Annual HCW Bioconnect Investor Conference

May 9, 2024, 10:54 AM EDT - 1 year ago

Akebia Therapeutics, Inc. (AKBA) Q1 2024 Earnings Call Transcript

May 9, 2024, 7:00 AM EDT - 1 year ago

Akebia Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

May 2, 2024, 8:30 AM EDT - 1 year ago

Akebia Therapeutics to Report First Quarter 2024 Financial Results and Discuss Recent Business Highlights

Apr 4, 2024, 5:56 PM EDT - 1 year ago

Buy Vafseo's Approval: A New Chapter For Akebia Therapeutics In Anemia Management

Mar 27, 2024, 8:45 PM EDT - 1 year ago

U.S. FDA approves Akebia's anemia drug

Mar 27, 2024, 8:26 PM EDT - 1 year ago

Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis

Mar 14, 2024, 4:15 PM EDT - 1 year ago

Akebia Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

Mar 11, 2024, 5:05 PM EDT - 1 year ago

Akebia Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results

Jan 30, 2024, 8:00 AM EST - 1 year ago

Akebia Secures $55 Million Term Loan Financing

Jan 9, 2024, 8:30 AM EST - 1 year ago

Akebia Therapeutics Announces Appointment of Nicholas Grund as Chief Commercial Officer

Dec 20, 2023, 8:00 AM EST - 1 year ago

Akebia Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Nov 20, 2023, 8:00 AM EST - 1 year ago

Akebia Therapeutics to Present at Piper Sandler Healthcare Conference

Nov 8, 2023, 2:18 PM EST - 1 year ago

Akebia Therapeutics, Inc. (AKBA) Q3 2023 Earnings Call Transcript

Nov 8, 2023, 7:30 AM EST - 1 year ago

Akebia Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Nov 3, 2023, 5:52 PM EDT - 1 year ago

Akebia Therapeutics: Waiting For Round 2